Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTXNASDAQ:MGXNASDAQ:PMVPOTCMKTS:PRVCF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$5.01+1.4%$4.44$3.39▼$16.00$53.49M0.7763,829 shs22,006 shsMGXMetagenomi$1.65+2.7%$1.59$1.23▼$5.50$60.18M-0.38840,010 shs262,662 shsPMVPPMV Pharmaceuticals$1.21+10.0%$0.99$0.81▼$1.82$57.15M1.49197,978 shs582,828 shsPRVCFPreveCeutical Medical$0.03+4.0%$0.03$0.01▼$0.03$14.21M0.3433,756 shs66,918 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+1.42%+5.25%+13.86%-13.62%-56.96%MGXMetagenomi+2.73%+4.03%-6.55%+17.30%-57.70%PMVPPMV Pharmaceuticals+10.00%+12.04%+31.62%+21.00%-22.44%PRVCFPreveCeutical Medical+4.02%-6.50%-14.24%+94.74%+89.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics3.0535 of 5 stars3.53.00.00.02.01.71.3MGXMetagenomi1.8108 of 5 stars3.52.00.00.00.01.70.6PMVPPMV Pharmaceuticals2.5236 of 5 stars3.53.00.00.00.62.50.6PRVCFPreveCeutical MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 3.00Buy$30.00498.80% UpsideMGXMetagenomi 3.00Buy$13.00685.97% UpsidePMVPPMV Pharmaceuticals 3.00Buy$5.50354.55% UpsidePRVCFPreveCeutical Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRVCF, MGX, PMVP, and AVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.005/15/2025MGXMetagenomiChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.005/14/2025MGXMetagenomiWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.00 ➝ $16.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$441K123.01N/AN/A$12.80 per share0.39MGXMetagenomi$52.29M1.18N/AN/A$6.28 per share0.26PMVPPMV PharmaceuticalsN/AN/AN/AN/A$3.40 per shareN/APRVCFPreveCeutical MedicalN/AN/AN/AN/A($0.01) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A111.00%58.88%8/11/2025 (Estimated)MGXMetagenomi-$78.06M-$2.11N/AN/AN/A-172.21%-31.21%-22.21%8/13/2025 (Estimated)PMVPPMV Pharmaceuticals-$58.71M-$1.18N/AN/AN/AN/A-32.54%-29.59%8/6/2025 (Estimated)PRVCFPreveCeutical Medical-$940KN/A0.00∞N/AN/AN/AN/AN/ALatest PRVCF, MGX, PMVP, and AVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MGXMetagenomi-$0.62-$0.68-$0.06-$0.68$8.75 million$4.13 million5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/A5/9/2025Q1 2025PMVPPMV Pharmaceuticals-$0.37-$0.34+$0.03-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/APRVCFPreveCeutical MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A22.6122.61MGXMetagenomiN/A5.855.85PMVPPMV PharmaceuticalsN/A16.7516.75PRVCFPreveCeutical MedicalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%MGXMetagenomiN/APMVPPMV Pharmaceuticals90.20%PRVCFPreveCeutical MedicalN/AInsider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics3.03%MGXMetagenomi17.80%PMVPPMV Pharmaceuticals7.57%PRVCFPreveCeutical MedicalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4010.83 million10.50 millionNot OptionableMGXMetagenomi23637.38 million30.73 millionN/APMVPPMV Pharmaceuticals5051.95 million48.02 millionOptionablePRVCFPreveCeutical MedicalN/A570.65 millionN/ANot OptionablePRVCF, MGX, PMVP, and AVTX HeadlinesRecent News About These CompaniesPRVCF PreveCeutical Medical Inc. - Seeking AlphaJuly 2 at 9:09 PM | seekingalpha.comPreveCeutical Appoints Dr. Francis Tavares as CTO to Enhance Drug Discovery EffortsJune 30, 2025 | tipranks.comPreveCeutical Welcomes Dr. Francis Tavares, PhD. As Chief Technology OfficerJune 30, 2025 | newsfilecorp.comNPreveCeutical Medical (OTCMKTS:PRVCF) versus Minerva Neurosciences (NASDAQ:NERV) Head-To-Head ReviewJune 29, 2025 | americanbankingnews.comPreveCeutical Announces Date for Annual General and Special MeetingJune 25, 2025 | newsfilecorp.comNPreveCeutical Announces Non-Brokered Private PlacementJune 11, 2025 | newsfilecorp.comNPreveCeutical Appoints Dr. Deepak Sampath as Corporate AdvisorJune 2, 2025 | tipranks.comPreveCeutical Appoints Stephen Glover as Corporate Advisor to Boost Strategic GrowthMay 26, 2025 | tipranks.comPreveCeutical Welcomes Stephen Glover as Corporate AdvisorMay 26, 2025 | newsfilecorp.comNPreveCeutical Completes Private Placement to Boost R&D EffortsMay 22, 2025 | tipranks.comPreveCeutical Closes Final Tranche of Up-Sized Non-Brokered Private PlacementMay 22, 2025 | newsfilecorp.comNPreveCeutical’s BioGene Launches New Website to Boost Digital EngagementMay 14, 2025 | tipranks.comPreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc. ...May 14, 2025 | gurufocus.comPreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc., Expanding Its Digital Presence to Enhance Accessibility and Awareness of Innovative TherapiesMay 14, 2025 | newsfilecorp.comNPreveCeutical Closes Initial Tranche of Private Placement, Raising $590,001April 28, 2025 | tipranks.comPreveCeutical Closes Initial Tranche of Up-Sized Non-Brokered Private PlacementApril 28, 2025 | newsfilecorp.comNPreveCeutical Upsizes Private Placement to Bolster Financial PositionApril 15, 2025 | tipranks.comPreveCeutical Announces Up-Sized Non-Brokered Private PlacementApril 14, 2025 | newsfilecorp.comNPreveCeutical Announces Update to Non-Brokered Private PlacementApril 2, 2025 | newsfilecorp.comNPreveCeutical Launches Private Placement to Raise $500,000April 2, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRVCF, MGX, PMVP, and AVTX Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$5.01 +0.07 (+1.42%) Closing price 07/3/2025 01:33 PM EasternExtended Trading$5.01 0.00 (0.00%) As of 07/3/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Metagenomi NASDAQ:MGX$1.65 +0.04 (+2.73%) Closing price 07/3/2025 03:43 PM EasternExtended Trading$1.66 +0.00 (+0.06%) As of 07/3/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.PMV Pharmaceuticals NASDAQ:PMVP$1.21 +0.11 (+10.00%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$1.21 0.00 (0.00%) As of 07/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.PreveCeutical Medical OTCMKTS:PRVCF$0.03 +0.00 (+4.02%) As of 07/3/2025 11:28 AM EasternPreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity. PreveCeutical Medical Inc. is headquartered in West Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
